Bioteque (ROCO:4107) ROCE %: 19.27% (As of Dec. 2025)

What is Bioteque ROCE %?

Bioteque ROCO:4107 +0.87% 84 ROCE % is 19.27% as of Dec. 2025. GuruFocus rates ROCO:4107 with a GF Score™ of 84/100 and a GF Value™ of NT$129.00 (Modestly Undervalued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bioteque's annualized ROCE % for the quarter that ended in Dec. 2025 was 19.27%.

Bioteque (ROCO:4107) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bioteque ROCE % Related Terms

Bioteque ROCE % Historical Data

* Premium members only.

The historical data trend for Bioteque's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioteque ROCE % Chart

Bioteque Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

16.86

17.50

14.74

17.07

16.65

Bioteque Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROCE %	Get a 7-Day Free Trial															17.79	17.46	14.16	18.25	19.27

84GF Score

Bioteque Corp ROCO:4107

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Bioteque ROCE % Calculation

Bioteque's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	682.162	/	( ( (4645.411 - 565.348)	+	(4659.999 - 546.665) )	/ 2 )
	=	682.162	/	( (4080.063	+	4113.334)	/ 2 )
	=	682.162	/	4096.6985
	=	16.65 %

Bioteque's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	778.644	/	( ( (4491.896 - 522.802)	+	(4659.999 - 546.665) )	/ 2 )
	=	778.644	/	( ( 3969.094	+	4113.334 )	/ 2 )
	=	778.644	/	4041.214
	=	19.27 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 19.27% mean?

Bioteque (ROCO:4107) has a ROCE % of 19.27% as of Dec. 2025.

Is Bioteque's ROCE % too high?

Bioteque's current ROCE % is 19.27%. The Medical Devices & Instruments industry median ROCE % is 2.20. Bioteque's value of 19.27% is 775.9% above this industry median. Overall, Bioteque has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Bioteque's ROCE % compare to ISRG and BDX?

Bioteque's ROCE % of 19.27% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. Bioteque's value of 19.27% is 775.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioteque's current ROCE % of 19.27% is 775.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioteque's current ROCE % is 19.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Bioteque stock overvalued right now?

Based on GuruFocus' analysis, Bioteque (ROCO:4107) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$129.00, compared to a current price of NT$116.50 — trading 9.7% below its estimated fair value. The current ROCE % is 19.27% and 775.9% above the Medical Devices & Instruments industry median of 2.20. Bioteque's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Bioteque (ROCO:4107), the current ROCE % is 19.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioteque (ROCO:4107) Overvalued in 2026?

Based on GuruFocus' analysis, Bioteque stock appears to be undervalued. The current stock price of NT$116.50 is trading 9.7% below its estimated GF Value™ of NT$129.00. GuruFocus considers Bioteque to be Modestly Undervalued.

Key valuation signals for ROCO:4107:

ROCE %: 19.27%
GF Value™: NT$129.00 vs. price of NT$116.50 (9.7% below fair value)
GF Score™: 84/100
Industry Position: 775.9% above the Medical Devices & Instruments median

No single metric tells the full story. See the ROCO:4107 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioteque Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ROCO:6499 ROCO:4126 ROCO:5312 TPE:4771 ROCO:1565 TPE:4737 TPE:6782 TPE:1786 TPE:1783 ROCO:6612 ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543

Address Chang-An E. Road, 5th Floor-6, No.23, Section 1, Taipei, TWN, 104

Website https://www.bioteq.com.tw

Bioteque Corp is engaged in manufacturing, trading, and selling medical equipment and instruments. The company operates in different segments such as Manufacturing medical disposables for hemodialysis use, and selling them to dealers and retailers; Manufacturing and selling catheters for healthcare and medical PVC IV bags to medical organizations; Manufacturing and selling medical key components and inner catheters to the medical organization; and Other segment. Geographically, the company generates a majority of its revenue from Asia and the rest from North America, South America, and other regions.

84GF Score

Get the complete analysis for ROCO:4107

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$116.50

Price

NT$129.00

GF Value

View ROCO:4107 Analysis

See ROCE % data for all stocks →